Telomir Pharmaceuticals announces $3M in equity financing

Telomir has secured $3M in equity financing, through a direct investment by The Bayshore Trust, the Company’s largest shareholder. The transaction involved the purchase of 1M restricted shares of the Company’s common stock at $3.00 per share, representing an 18% premium to Telomir’s closing share price of $2.54 on the date of execution. The transaction was structured as a straight restricted common stock transaction with no warrants, no discounts, and no convertible features. This transaction follows a prior $1M equity investment at $7.00 per share made on December 9, 2024, through The Starwood Trust-an entity affiliated with the Company’s largest shareholder – and complements an existing $5M non-dilutive line of credit from the same affiliated group, which remains undrawn.